ProPhase Labs Valuation
| PRPH Stock | USD 0.20 0.01 4.76% |
ProPhase Labs seems to be undervalued based on Macroaxis valuation methodology. Our model determines the value of ProPhase Labs from analyzing the company fundamentals such as Return On Equity of -2.2, current valuation of 8.14 M, and Shares Owned By Insiders of 5.51 % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that ProPhase Labs' price fluctuation is dangerous at this time. Calculation of the real value of ProPhase Labs is based on 3 months time horizon. Increasing ProPhase Labs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ProPhase Labs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ProPhase Stock. However, ProPhase Labs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.2 | Real 3.6 | Hype 0.25 | Naive 0.15 |
The intrinsic value of ProPhase Labs' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence ProPhase Labs' stock price.
Estimating the potential upside or downside of ProPhase Labs helps investors to forecast how ProPhase stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ProPhase Labs more accurately as focusing exclusively on ProPhase Labs' fundamentals will not take into account other important factors: ProPhase Labs Total Value Analysis
ProPhase Labs is at this time projected to have valuation of 8.14 M with market capitalization of 829.2 K, debt of 24.57 M, and cash on hands of 27.5 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ProPhase Labs fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.14 M | 829.2 K | 24.57 M | 27.5 M |
ProPhase Labs Investor Information
The company has price-to-book ratio of 0.13. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. ProPhase Labs recorded a loss per share of 19.8. The entity last dividend was issued on the 24th of May 2022. The firm had 1:10 split on the 22nd of December 2025. Based on the key indicators related to ProPhase Labs' liquidity, profitability, solvency, and operating efficiency, ProPhase Labs is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.ProPhase Labs Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ProPhase Labs has an asset utilization ratio of 10.71 percent. This signifies that the Company is making $0.11 for each dollar of assets. An increasing asset utilization means that ProPhase Labs is more efficient with each dollar of assets it utilizes for everyday operations.ProPhase Labs Ownership Allocation
ProPhase Labs holds 5.51 pct. of its outstanding shares held by insiders and 5.03 pct. owned by third-party entities.ProPhase Labs Profitability Analysis
The company reported the previous year's revenue of 6.77 M. Net Loss for the year was (49.52 M) with profit before overhead, payroll, taxes, and interest of 987 K.About ProPhase Labs Valuation
An absolute valuation paradigm, as applied to ProPhase Stock, attempts to find the value of ProPhase Labs based on its fundamental and basic technical indicators. By analyzing ProPhase Labs's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of ProPhase Labs's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of ProPhase Labs. We calculate exposure to ProPhase Labs's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ProPhase Labs's related companies.ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Prophase Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 129 people.
ProPhase Labs Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.9 M | |
| Quarterly Earnings Growth Y O Y | -0.952 | |
| Forward Price Earnings | 10.0908 |
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |